Zevra Therapeutics
Open
$10.24
Prev. Close
$10.24
High
$10.24
Low
$10.16
Market Snapshot
$544.4M
6.5
-2.26
$23.61M
61
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 61 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
emptyResult
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 61 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Recently from Cashu
Insider Transaction Boosts Leadership Confidence at Zevra Therapeutics Amid Pipeline Advancements
Leadership Confidence at Zevra Therapeutics Highlighted by Insider Transaction Zevra Therapeutics observes a significant insider transaction that underscores the confidence its leadership has in the c…
Zevra Therapeutics Sells SDX Portfolio to Commave for $50 Million to Focus on Core Initiatives
Zevra Therapeutics Divests SDX Portfolio to Commave Therapeutics for $50 Million Zevra Therapeutics announces that Commave Therapeutics SA acquires its serdexmethylphenidate (SDX) portfolio for $50 mi…
Zevra Therapeutics Transfers ADHD Portfolio to Commave Therapeutics for Strategic Focus and Growth
Zevra Therapeutics Transfers ADHD Assets to Commave Therapeutics in Strategic Move Zevra Therapeutics makes a significant strategic shift by announcing the acquisition of its serdexmethylphenidate (SD…
Innovative Strategies to Address Niemann-Pick Disease Type C and Enhance Patient Outcomes
Innovative Approaches in Niemann-Pick Disease Type C Treatment Zevra Therapeutics focuses its efforts on addressing the challenges posed by Niemann-Pick disease type C (NPC), a rare and inherited neur…